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Abstract
Background: Neuroserpin has shown neuroprotective effects in animal models of cerebral ischemia and has been
associated with functional outcome after ischemic stroke. Our aim was to study whether neuroserpin serum levels
could be associated to biomarkers of excitotoxicity, inflammation and blood brain barrier disruption.
Methods: We prospectively included 129 patients with ischemic stroke (58.1% male; mean age, 72.4 ± 9.6 years)
not treated with tPA within 12 hours (h) of symptoms onset (mean time, 4.7 ± 2.1 h). Poor functional outcome at
3 months was considered as a modified Rankin scale score >2. Serum levels of neuroserpin, Interleukin 6 (IL-6),
Intercellular adhesion molecule-1 (ICAM-1), active Matrix metalloproteinase 9 (MMP-9), and cellular fibronectin (cFn)
(determined by ELISA) and glutamate (determined by HPLC) were measured on admission, 24 and 72 h. The main
variable was considered the decrease of neuroserpin levels within the first 24 h. ROC analysis was used to select
the best predictive value for neuroserpin to predict poor functional outcome due to a lack of linearity.
Results: The decrease of neuroserpin levels within the first 24 h was negatively correlated with serum levels at
24 hours of glutamate (r = -0.642), IL-6 (r = -0.678), ICAM-1 (r = -0.345), MMP-9 (r = -0.554) and cFn (r = -0.703) (all P <
0.0001). In the multivariate analysis, serum levels of glutamate (OR, 1.04; CI95%, 1.01-1.06, p = 0.001); IL-6 (OR, 1.4; CI95%,
1.1-1.7, p = 0.001); and cFn (OR, 1.3; CI95%, 1.1-1.6, p = 0.002) were independently associated with a decrease of
neuroserpin levels <70 ng/mL at 24 h after adjusting for confounding factors.
Conclusions: These findings suggest that neuroprotective properties of neuroserpin may be related to the
inhibition of excitotoxicity, inflammation, as well as blood brain barrier disruption that occur after acute ischemic
stroke.
Background
Several studies have shown that the serin protease inhibi-
tor, neuroserpin, exerts a neuroprotective effect after
brain ischemia, probably due to its natural ability to form
an inactivating complex with tissue plasminogen activa-
tor (tPA). It is also known that tPA is able to promote
neuronal injury in the brain parenchyma by enhancing
different mechanisms, such as the activation of microglia
[1] as well as affecting neuronal N-methyl-D-aspartate
(NMDA) receptor-mediated signalling [2]. This leads to
an increased release of cytotoxic agents, such as inflam-
matory mediators, a matrix metalloproteinase-mediated
digestion of the extracellular matrix and a glutamate-
induced excitotoxicity. The effect of neuroserpin on
reducing this tPA-induced damage in the brain has been
studied, and both the overexpression of neuroserpin [3]
and neuroserpin treatment after cerebral ischemia [4,5]
have proved to be effective in reducing the final lesion.
Furthermore, an association between neuroserpin
serum levels and functional outcome in patients with
ischemic stroke has recently been reported [6]. In the
present study, we sought to investigate whether neuroser-
pin serum levels in patients with ischemic stroke could
be associated to serum levels of different molecules of
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the ischemic cascade. Thus, glutamate was measured as a
marker of excitotoxic damage, interleukin-6 (IL-6) and
Intercellular Adhesion Molecule-1 (ICAM-1) as markers
of inflammatory response, and matrix metalloproteinase
9 (MMP-9) and cellular fibronectin (cFn) as markers of
blood brain barrier disruption after ischemic stroke.
Patients and methods
Study population and patients characteristics
One hundred and ninety patients with a first-ever
ischemic stroke of less than 12 hours from symptoms
onset, and previously independent for their daily living
activities, were prospectively evaluated to be included in
the study. Patients with chronic inflammatory diseases
(n = 5), severe hepatic (n = 4), renal (n = 2) or hematolo-
gical diseases (n = 2), cancer (n = 4) or infectious disease
in the 15 days prior to inclusion (n = 5) were excluded
due to their impact on stroke outcome and possible
interference in neuroserpin levels. Sample size was calcu-
lated using EPIDAT software http://www.sergas.es/Mos-
trarContidos_N3_T01.aspx?IdPaxina=62715 assuming
alpha and beta errors of 0.05 and 0.2, respectively.
Likewise, 26 patients who had received thrombolytic
treatment were excluded in order to assess the neuro-
protective role of neuroserpin without the disturbance
of rtPA. Seven patients did not accept to participate and
6 patients were lost during the follow-up, therefore, a
total of 129 patients were finally included in the study.
This research was carried out in accordance with the
Declaration of Helsinki of the World Medical Associa-
tion (2000) and approved by the Ethics Committee of
the participating hospital. Informed consent was
obtained from each patient or their relatives after full
explanation of the procedures.
Clinical variables
All patients were admitted to an acute stroke unit and
treated following the European Stroke Organization
guidelines [7]. Medical history recording potential vascu-
lar risk factors, blood and coagulation tests, 12-lead
ECG, chest radiography, and carotid ultrasonography
were performed on admission. Stroke subtype was clas-
sified according to the TOAST criteria as atherothrom-
botic (n = 23), cardioembolic (n = 54), lacunar (n = 15),
and undetermined (n = 37) [8]. Stroke severity was
assessed by a internationally certified neurologist using
the National Institute of Health Stroke Scale (NIHSS)
on admission, 24 ± 6 hours, 48 ± 6 hours, 72 ± 24
hours, and at 7 ± 1 and 90 ± 7 days. Early neurological
deterioration (END) was diagnosed in those patients
who worsened 4 or more points on NIHSS score within
the first 48 hours. Functional outcome was evaluated at
3 months using the modified Rankin Scale (mRS), con-
sidering a score >2 as poor outcome.
Neuroimaging variables
CT scans were carried out on admission and between
days 4 and 7. Infarct volume was calculated in the sec-
ond CT by using the formula 0.5 × a × b × c, where a
and b are the largest perpendicular diameters, and c is
the number of 1-cm thick sections that contain the
lesion. All neuroimaging evaluations were made by the
same neuroradiologist who had no knowledge of the
patients’ clinical and laboratory results.
Laboratory determinations
Serum glucose, platelet count and coagulation tests were
assessed in a central laboratory. Blood samples, drawn
from all patients on admission, at 24 ± 6 and 72 ± 24
hours, were collected in glass chemistry test tubes, cen-
trifuged at 3000 xg for 10 minutes, and serum immedi-
ately frozen and stored at -80°C until analysis.
Glutamate levels, as a biomarker of excitotoxicity, were
determined by HPLC, using the Waters Pico Tag®
Chemistry Package for HPLC amino acids analysis. IL-6
and ICAM-1, as indexes of inflammatory response, were
determined by IMMULITE 1000 System (Siemens) and
a commercially available sandwich enzyme-linked inmu-
nosorbent assay (ELISA) kit from Bender Medsystems,
respectively. Finally, as blood brain barrier disruption
markers, active MMP-9 and cFn were determined using
GE Healthcare and Biohit Plc ELISA kits, respectively.
For neuroserpin quantification, a sandwich ELISA was
performed as described previously [6,9,10]. Each sample
was assayed in duplicate and intra-assay coefficients of
variation sample values were always <15%. Clinical
investigators were unaware of the laboratory results
until the end of the study, once the database was closed.
The absolute difference between basal and 24 hours
neuroserpin levels was defined as neuroserpin decrease.
All determinations were carried out in a laboratory
blind to the clinical outcome and neuroimaging findings.
Endpoints
The primary endpoint was the decrease of neuroserpin
levels at 24 hours.
Statistical analysis
For continuous variables, we tested if data presented a
Normal distribution using the Kolgomorov-Smirnov test.
Parametric tests were used if they followed a Normal dis-
tribution and non-parametric tests if they did not. Mann-
Whitney test was used for continuous variables with
non-Normal distribution, Student’s t test for continuous
variables with Normal distribution and Chi-square test
for proportions between patients. In addition Spearman
analysis was used for bivariate correlations with non-
Normal distribution. Results are expressed as percentages
for categorical variables and as mean (SD) or median
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[quartiles] for the continuous variables depending on
their normal distribution or not. Neuroserpin was used
as a continuous variable since there was a linearity of the
odds ratios for outcome. The influence of neuroserpin
decrease at 24 h on serum levels of molecular markers of
brain injury was assessed by logistic regression analysis,
after adjusting for the main baseline variables related to
neuroserpin decrease in the univariate analysis (enter
approach and probability of entry P < 0.05). Due to a lack
of linearity, the decrease of neuroserpin levels at
24 hours was categorized by ROC analysis. Results were
expressed as adjusted odds ratios (OR) with the corre-
sponding 95% confidence intervals (95% CI). The statisti-
cal analysis was conducted using SPSS 16.0 for Windows
XP.
Results
A total of 129 patients (58.1% male; mean age 72.4 ± 9.6
years) who did not receive thrombolytic treatment were
prospectively included in the study within 12 hours of
symptoms onset (mean time 4.7 ± 2.1 hours). The
NIHSS score on admission was 9 [4,14] . Neuroserpin
levels on admission were significantly greater [148.4 ±
37.7 ng/mL] than at 24 hours [79.1 ± 52.3 ng/mL] or at
72 hours [80.9 ± 60.5 ng/mL] (all p <0.0001). No differ-
ences in neuroserpin levels between 24 and 72 hours
were found. Median neuroserpin decrease within the
first 24 hours was 69.4 ± 51.5 ng/mL.
A decrease in neuroserpin levels <70 ng/mL within
the first 24 hours predicted the probability of poor out-
come (area under curve 0.921, P < 0.0001) with the
highest sensitivity (84%) and specificity (91%). For this
reason, our analysis focused on those molecular markers
of brain injury which were positively associated with a
decrease in neuroserpin levels <70 ng/mL at 24 hours.
Neuroserpin and brain injury biomarkers
We evaluated the relationship between neuroserpin levels
and brain injury biomarkers on admission as well as
between neuroserpin decrease within the first 24 hours
and biomarkers serum levels at 24 hours from stroke
onset. We did not find a significant correlation between
neuroserpin serum levels on admission and glutamate (r =
-0.138, p = 0.133), IL-6 (r = -0.062, p = 0.485), ICAM-1 (r
= 0.004, p = 0.964), active MMP-9 (r = 0.143, p = 0.224)
or cFn (r = -0.139, p = 0.117). However, the decrease of
neuroserpin levels within the first 24 h was negatively cor-
related with serum levels of brain injury biomarkers at
24 hours: glutamate (r = -0.642), IL-6 (r = -0.678), ICAM-
1 (r = -0.345), active MMP-9 (r = -0.554), cFn (r = -0.703),
(all P < 0.0001) (Figure 1).
Our analysis showed that patients with a decrease of
neuroserpin levels within the first 24 hours < 70 ng/mL
presented greater serum levels of glutamate, IL-6,
ICAM-1, active MMP-9 and cFn at 24 hours (Table 1).
In the multivariate analysis, serum levels of glutamate
(OR, 1.04; CI 95%, 1.01-1.06, p = 0.001), IL-6 (OR, 1.4;
CI 95%, 1.1 - 1.7, p = 0.001) and cFn (OR, 1.3; CI 95%,
1.1 - 1.6, p = 0.002) were independently associated with
a decrease of neuroserpin levels < 70 ng/mL after
adjustment for age, sex, previous stroke, lesion volume,
glucose levels and baseline stroke severity (Table 2).
Discussion
Neuroserpin has extensively shown neuroprotective
activity after brain ischemia in experimental models
[3-5]. In addition, an association between neuroserpin
levels and acute ischemic stroke outcome has recently
been reported [6]. However, the mechanisms that are
involved in neuroserpin-mediated neuroprotection
remain to be well characterized. In order to investigate
this, the present study has explored the association
between neuroserpin serum levels and established bio-
markers of different mechanisms of brain injury which
take place after acute ischemic stroke.
The implication of the selected biomarkers in different
pathophysiological mechanisms that are triggered by
ischemic stroke as well as their clinical value, have been
extensively investigated and validated in previous studies
carried out by our group as well as by others [10-20].
Hence, glutamate was selected as a biomarker of excito-
toxic damage, ICAM-1 and IL-6 as inflammatory bio-
markers, and MMP-9 as well as cFn as blood brain
barrier disruption biomarkers. We did not find any sig-
nificant statistical relationship between serum levels of
neuroserpin and the selected biomarkers at baseline.
However, a negative correlation was found between
serum levels of all the biomarkers at 24 hours and neu-
roserpin decrease within the first 24 hours after stroke
onset. Using ROC analysis, we had established a 70 ng/
mL cut-off value for the decrease of neuroserpin serum
levels within the first 24 hours to predict poor outcome.
The results of the present study show a significant asso-
ciation between neuroserpin decrease < 70 ng/mL and
serum levels of brain injury biomarkers at 24 hours,
which remained independent for glutamate, IL-6 and
cFn after adjusting for confounding factors.
Neuroserpin displays a neuroprotective effect in
rodent models of cerebral ischemia [3-5] by inhibiting
extravascular deleterious effects of tPA in the brain par-
enchyma. Due to the fact that patients treated with tPA
were excluded in our study, neuroserpin would presum-
ably be acting on endogenous tPA, whose expression
increases after brain ischemia [4,21].
It has been demonstrated that tPA exacerbates gluta-
mate-mediated excitotoxicity by its interaction with
NMDA receptor [22,23] and also that neuroserpin is
able to protect neurons from NMDA-induced neuronal
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death both in vitro and in vivo [24], probably by limiting
this deleterious tPA-mediated effect on glutamatergic
signalling. Our results show a significant relationship
between a greater neuroserpin decrease in serum within
the first 24 h after stroke onset and lower glutamate
serum levels at 24 hours. This result seems to be in
accordance with experimental studies, suggesting that
neuroserpin might affect glutamate-mediated excitotoxic
response after ischemic stroke.
We have also found significant relationships between a
greater neuroserpin decrease within the first 24 hours
from stroke onset and lower levels of the inflammatory
biomarkers ICAM-1 and IL-6 at 24 hours. Previous stu-
dies by our group have reported associations between
serum levels of these inflammatory markers and clinical
features such as early neurological deterioration, greater
final infarct volume and cerebral edema [14,25]. It is
known that tPA, whose expression increases after brain
ischemia, activates microglial cells which produce inflam-
matory molecules that promote neuronal damage [26,27].
In addition, some of these molecules, like tumour necro-
sis factor alpha (TNF-a) or interleukin-1 beta (IL-1b)
strongly up-regulate the expression of adhesion mole-
cules such as ICAM-1 [28], thus contributing to the
extension of the lesion. Likewise, the extracellular matrix
substrate fibronectin is able to promote microglial activa-
tion [29-31].
It has also been proposed that neuroserpin could
reduce microglial activation after ischemic stroke due to
its ability to form tPA-inactivating complexes in the
brain parenchyma [3]. Because neuroserpin serum levels
within the first 24 hours are associated with a lower
level of the inflammatory biomarkers ICAM-1 and IL-6
at 24 hours, we hypothesize that those patients who
show more severe clinical outcome might require more
neuroserpin in the brain parenchyma to inactivate tPA,
and this could lead to lower neuroserpin levels in
serum. Neuroserpin, via complex formation with tPA,
could limitate microglial activation, therefore the pro-
duction of inflammatory mediators would be reduced, as
reflected by the decreased serum levels observed.
Likewise, after ischemia, an increase in neuroserpin
contributes to preserving the integrity of the basement
membrane [4] and decreases blood brain barrier leakage,
reducing ischemic lesion [5]. MMP-9 is an endopeptidase
which mediates extracellular matrix degradation, and gly-
coprotein fibronectin is one of its substrates [32]. There
is abundant evidence indicating that increased MMP-9
expression after ischemia significantly contributes to
basal lamina degradation, thus leading to hemorrhagic
Figure 1 Significant correlations between neuroserpin decrease within the first 24 hours and levels of molecular markers of brain
damage at 24 hours.
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transformation of ischemic stroke [18,33-36]. It has also
been proved that tPA enhances MMP-9 expression in
vitro and in vivo [37,38]. Furthermore, tPA-treated
patients show increased plasma levels of MMP-9 [39].
Recent results from our group have also shown a nega-
tive correlation between neuroserpin decrease within the
first 24 hours and MMP-9 levels at 24 hours in patients
treated with tPA [6], which is in line with the results of
the present manuscript, where a greater decrease in neu-
roserpin serum levels within the first 24 hours was corre-
lated with lower serum levels of MMP-9 at 24 hours.
Accordingly, we postulate that greater expression of neu-
roserpin in the brain parenchyma could contribute to
stronger downregulation of tPA activity, therefore, redu-
cing tPA-induced MMP-9 expression.
Conclusions
In conclusion, we have found a negative correlation
between the decrease in neuroserpin serum levels within
the first 24 hours and levels of molecular markers of
brain damage at 24 hours after ischemic stroke. We sug-
gest that neuroprotective properties of neuroserpin
might be related to the inhibition of tPA-mediated
mechanisms of excitotoxicity, inflammation, as well as
blood brain barrier disruption that occur after acute
ischemic stroke. This is in line with recent results from
Table 1 Univariate analysis for neuroserpin decrease
Neuroserpin decrease
within first 24 h ≥70 ng/mL
n = 70
Neuroserpin decrease
within first 24 h <70 ng/mL
n = 59
p
Female, % 30.0 55.9 0.003
Age, years 69.9 ± 10.6 75.2 ± 7.5 0.004
Time from onset, h 4.8 ± 2.2 4.5 ± 2.1 0.816
TOAST 0.051
- Atherothrombotic, % 17.1 18.6
- Cardioembolic, % 35.7 49.2
- Lacunar, % 18.6 3.4
- Indeterminated, % 28.6 28.8
History of hypertension, % 57.1 69.5 0.103
History of diabetes, % 22.9 28.8 0.284
History of dyslipemia, % 21.4 25.4 0.371
History of atrial fibrillation, % 20.0 32.2 0.084
Previous stroke, % 2.9 15.3 0.013
Systolic BP on admission, mm Hg 147.9 ± 23.6 145.6 ± 18.8 0.885
Diastolic BP on admission, mm Hg 81.3 ± 14.2 71.6 ± 12.2 0.062
Maximum temperature 24 h (°C) 36.7 ± 0.4 36.7 ± 0.5 0.943
Glycemia, mg/dL 120.4 ± 25.3 183.7 ± 87.4 0.001
Leukocyte count, 103/mL 8.7 ± 2.4 9.2 ± 2.8 0.427
Fibrinogen, mg/dL 386.9 ± 105.2 428.1 ± 136.2 0.080
Early neurological deterioration, % 2.9 25.4 <0.0001
NIHSS on admission 5 [3,10] 14 [10,16] <0.0001
Infarct volume, mL 18.2 ± 20.9 44.4 ± 36.3 <0.0001
Molecular markers of brain damage
Glutamate 24 h, μM 67.7 ± 54.4 149.9 ± 36.3 <0.0001
IL-6 24 h, pg/mL 18.4 ± 3.2 29.2 ± 8.1 <0.0001
ICAM-1 24 h, ng/mL 344.7 ± 122.5 430.2 ± 79.1 <0.0001
Active MMP-9 24 h, ng/mL 23.9 ± 8.7 32.3 ± 11.1 <0.0001
cFn 24 h, μg/mL 7.6 ± 1.9 13.1 ± 5.6 <0.0001
Baseline clinical characteristics, stroke subtype, vascular risk factors, biochemical parameters, neuroimaging findings and molecular markers of brain damage in
patients with a neuroserpin decrease within the first 24 hours ≥ 70 ng/mL or < 70 ng/mL.
Table 2 Adjusted OR of neuroserpin decrease levels <70
ng/mL at 24 hours for serum levels of glutamate, IL-6,
ICAM-1, active MMP-9 and cFn at 24 hours
Adjusted OR (95% CI) p
Glutamate at 24 hours 1.04 (1.01 to 1.06) 0.001
IL-6 at 24 hours 1.4 (1.1 to 1.7) 0.001
ICAM-1 at 24 hours 1.0 (0.9 to 1.1) 0.065
Active MMP-9 at 24 hours 1.1 (0.9 to 1.3) 0.095
cFn at 24 hours 1.3 (1.1 to 1.6) 0.002
Adjusted for sex, age, previous stroke, glucose levels, NIHSS on admission and
infarct volume.
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our group obtained after investigating neuroserpin
effects using an in vitro model of brain ischemia [40].
The information reported here regarding biomarkers
might be relevant to evaluate the utility of neuroserpin
as a potential treatment for ischemic stroke patients. In
this respect, combined thrombolytic and neuroprotective
therapy continues to be one of the most interesting
approaches for ischemic stroke. This and future studies
could contribute to better molecular characterization of
the deleterious consequences of thrombolytic therapy,
and lead to the development of effective strategies to
reduce them.
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